Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Terminated · Phase 1, Phase 2 · NCT03747484
Conditions: Other Skin
At a glance
- Research payments reported, 2025
- $9,712
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 7
About the trial
- Sponsor
- Fred Hutchinson Cancer Center (with National Cancer Institute (NCI), Affini-T Therapeutics, Inc.)
- Tested
- Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR (biological), Avelumab (drug), Pembrolizumab (biological), Interferon Gamma-1b (biological)
- Dates
- Started 2019-07-03; completion 2024-01-09
- Results posted
- Yes
This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR) and to see how well they work in treating patients with Merkel cell cancer that has spread to other parts of the body (metastatic) or that cannot be removed by surgery (unresectable). Placing a gene that has been created in the laboratory into immune cells may improve the body's ability to fight Merkel cell cancer.
From ClinicalTrials.gov, last updated 2025-03-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $9,712 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fred Hutchinson Cancer Center $9,712
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.